PARP1 and neoplasm: A major barrier to initially effective therapies is the development of tumor cell resistance, which has been documented clinically for both platinum drugs and PARP inhibitors, the most promising approaches for treating HR‐associated cancers thus far described (Ang et al, 2013; Ledermann et al, 2014).